Daewoong Pharmaceutical has further strengthened the scientific foundation for global expansion by quantitatively elucidating how the pharmacological action of its type 2 diabetes treatment, Enblo, leads to actual blood glucose reduction.


Daewoong Pharmaceutical announced on the 8th that it presented a poster at the 2026 PAGE (Population Approach Group Europe) Conference, held in Europe from June 2 to June 5, sharing research results analyzing the correlation between drug exposure and blood glucose reduction effects of its new diabetes drug Enblo (ingredient: inavogliflozin).


Enblo is a type 2 diabetes treatment in the SGLT-2 inhibitor class developed by Daewoong Pharmaceutical and is the 36th domestically developed new drug in Korea. Its mechanism blocks the reabsorption of glucose in the kidneys, promoting its excretion through urine and thus lowering blood sugar. Notably, it demonstrates excellent blood glucose-lowering effects and safety even at a low dose of 0.3 mg, and is drawing attention for its therapeutic advantages in the areas of kidney disease and heart failure.


At the 2026 PAGE conference, Seoyeon Yoon, Clinical Researcher at Daewoong Pharmaceutical, is presenting research findings based on the Enblo integrated model. Daewoong Pharmaceutical

At the 2026 PAGE conference, Seoyeon Yoon, Clinical Researcher at Daewoong Pharmaceutical, is presenting research findings based on the Enblo integrated model. Daewoong Pharmaceutical

View original image

This study was conducted to analyze the quantitative relationship between increased urinary glucose excretion and reduction in glycated hemoglobin (HbA1c) following Enblo administration. A key feature of the research is the use of an integrated model that links data from various clinical studies on drug exposure, urinary glucose excretion, and changes in HbA1c. The study examined how much Enblo is absorbed and metabolized in the body, how this metabolism leads to increased urinary glucose excretion, and ultimately, how it affects the reduction of HbA1c, a long-term blood sugar indicator.


The analysis integrated data from 224 participants in 10 clinical trials conducted in Korean subjects and phase 3 clinical data from 151 Chinese patients with type 2 diabetes. HbA1c is a representative diabetes management indicator that reflects average blood glucose levels.


The results showed a quantitative relationship in which urinary glucose excretion increased after Enblo administration, resulting in a greater reduction in HbA1c. Additionally, Enblo's glucose-lowering effect was predicted to be stably maintained even in patients with impaired renal function, suggesting the possibility of broader prescriptions for diverse patient groups.


This study also found no significant pharmacokinetic differences between Korean and Chinese patients when comparing Enblo's effects, indicating that the same dosage can be safely and effectively administered to Chinese patients as to Korean patients. Daewoong Pharmaceutical plans to utilize these results as evidence for subsequent clinical development strategies, including global approvals and expanded indications.


Lead researcher Seunghwan Lee, Professor of Clinical Pharmacology at Seoul National University Hospital, stated, "This study is significant in that it quantitatively explains Enblo’s absorption and metabolism, urinary glucose excretion, and HbA1c reduction effects using an integrated model. It provides scientific evidence for a more precise understanding of Enblo’s clinical characteristics in type 2 diabetes patients with varying degrees of renal function."


Jaejin Na, Head of Clinical Medicine Center at Daewoong Pharmaceutical, said, "This research strengthens the scientific foundation for global market entry by confirming consistent pharmacokinetic characteristics not only in Korean but also in Chinese patients. Daewoong Pharmaceutical will continue to expand the scientific evidence for Enblo, solidifying the competitiveness of this domestically developed diabetes treatment in Asia and global markets."



The PAGE Conference is a prestigious international academic event in the field of quantitative pharmacology, analyzing the processes of drug absorption, distribution, metabolism, and excretion using mathematical modeling. Building on last year’s presentation of a population pharmacokinetics model describing Enblo’s absorption and excretion, Daewoong Pharmaceutical this year presented integrated evidence explaining everything from drug exposure to increased urinary glucose excretion and improved blood sugar, further solidifying the scientific rationale for global regulatory approval.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing